Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220583 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
A Phase 2 study of Head and Neck Cancer, sponsored by Radiation Therapy Oncology Group.
- Active
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT01220583 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 252 participants, roughly in line with the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target. The trial reports 20 study locations across 3 states.
The verdict
NCT01220583, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with chemotherapy or alone after surgery in treating salivary gland tumors. PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery.
Conditions Studied
Interventions
- DRUG cisplatin
- RADIATION intensity-modulated radiation therapy
- RADIATION 3-dimensional conformal radiation therapy
Study Locations (20)
Arizona
- Arizona Breast Cancer Specialists-Gilbert - Gilbert
- Arizona Center for Cancer Care-Peoria - Peoria
- Cancer Center at Saint Joseph's - Phoenix
- Arizona Breast Cancer Specialists-Phoenix - Phoenix
- Arizona Oncology-Deer Valley Center - Phoenix
- Arizona Breast Cancer Specialists - Scottsdale
- Arizona Breast Cancer Specialists-Scottsdale - Scottsdale
- Arizona Oncology Services Foundation - Scottsdale
- Arizona Center for Cancer Care-Surprise - Surprise
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
California
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
- Mills-Peninsula Medical Center - Burlingame
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- Mercy San Juan Medical Center - Carmichael
- City of Hope Comprehensive Cancer Center - Duarte
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- The Kirklin Clinic at Acton Road - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2011-01 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220583
The ClinicalTrials.gov registry entry for NCT01220583 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT01220583 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01220583 about?
NCT01220583 is a clinical study titled "Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effe...
What is the current status of trial NCT01220583?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2011-01. Estimated completion is 2028-10.
What conditions does trial NCT01220583 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT01220583?
The interventions under investigation include: cisplatin (DRUG), intensity-modulated radiation therapy (RADIATION), 3-dimensional conformal radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01220583?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01220583 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.